Rating Rationale
June 27, 2018 | Mumbai
Ayurvet Limited
Ratings Reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.15 Crore
Long Term Rating CRISIL A-/Stable (Reaffirmed)
Short Term Rating CRISIL A2+ (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has reaffirmed its 'CRISIL A-/Stable/CRISIL A2+' ratings on the bank facilities of Ayurvet Limited (AL).

The company's business risk profile is supported by established market position and the promoters' extensive experience, but is constrained by modest scale and stagnant revenue. Turnover declined in fiscal 2018 due to closure of the loss-making animal feed business. Sales growth and profitability in the animal healthcare segment were hit by weak demand in overseas markets and weakening of the dollar. However, overall business profile remains supported by diversified customer base and healthy operating profitability margins. Marketing initiatives to increase customer awareness and product penetration should support revenue growth over the medium term.
 
Financial risk profile remains healthy because of negligible debt. Liquidity stays ample, with net cash accrual after dividend payout likely to be more than sufficient to meet negligible debt obligation, incremental working capital requirement, and modular capital expenditure (capex) requirement, leading to low bank borrowing. This is reflected in sparse utilisation of bank line over the past 12 months. Liquidity is also supported by healthy cash and cash equivalent of Rs 9.59 crore as on March 31, 2018.

Key Rating Drivers & Detailed Description
Strengths
* Healthy financial risk profile: The financial risk profile is supported by healthy capital structure and debt protection metrics. Muted revenue growth and efficient working capital management led to low incremental working capital requirement, leading to low debt and healthy capital structure. With sustenance of efficient working capital cycle, sound profitability, and no significant, debt-funded capex plan, the financial risk profile should remain healthy over the medium term.
 
* Established position in the animal healthcare products market: Longstanding presence of over two decades in the healthcare business, aided by established brands such as Ruchamax, Mastilep, Exapar, and Superliv have helped build up a strong marketing network in domestic and overseas markets. AL has exclusive distributors in the international market, with one distributor in each country. Successful take-off of this segment will remain a key rating sensitivity factor.

Weakness:
* Modest scale: With turnover of Rs 90.3 crore in fiscal 2018, the scale remains small in the highly fragmented animal healthcare businesses. CRISIL believes that with the shutting down of the animal feeds business, expansion of the healthcare business to sustain revenue will remain a key sensitivity factor.
Outlook: Stable

CRISIL believes AL will maintain its healthy financial risk profile, supported by moderate accrual, and continue to benefit from its management's extensive experience. The outlook may be revised to 'Positive' if there is a significant increase in scale of operations and profitability, while liquidity and capital structure remain healthy. The outlook may be revised to 'Negative' if decline in revenue and profitability weakens business and financial risk profiles, or if large, debt-funded capex constrains liquidity.

About the Company

AL was incorporated as Dabur Ayurvet Ltd in 1992, and got its present name in 2002. The company is managed by Mr M J Saxena (managing director). It manufactures and markets herbal animal healthcare products.

Key Financial Indicators
As on/for the period ended March 31   2017 2016
Revenue Rs crore 109.7 110.5
Profit after tax Rs crore 10.3 8.9
PAT margin % 9.4 8.0
Adjusted debt/adjusted networth Times 0.01 0.07
Interest coverage Times 36.0 22.8
 

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of allotment Coupon
rate (%)
Maturity date Issue size (Rs cr) Rating assigned with outlook
 NA Cash Credit & Working Capital demand loan NA NA NA 13 CRISIL A-/Stable
 NA Letter of credit & Bank Guarantee NA NA NA 2 CRISIL A2+
Annexure - Rating History for last 3 Years
  Current 2018 (History) 2017  2016  2015  Start of 2015
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  13.00  CRISIL A-/Stable      27-06-17  CRISIL A-/Stable  17-03-16  CRISIL A-/Stable  28-05-15  CRISIL A-/Stable  CRISIL A-/Stable/ CRISIL A2+ 
Non Fund-based Bank Facilities  LT/ST  2.00  CRISIL A2+      27-06-17  CRISIL A2+  17-03-16  CRISIL A2+  28-05-15  CRISIL A2+  -- 
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Cash Credit & Working Capital demand loan 13 CRISIL A-/Stable Cash Credit & Working Capital demand loan 13 CRISIL A-/Stable
Letter of credit & Bank Guarantee 2 CRISIL A2+ Letter of credit & Bank Guarantee 2 CRISIL A2+
Total 15 -- Total 15 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for rating short term debt

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Jyoti Parmar
Media Relations
CRISIL Limited
D: +91 22 3342 1835
B: +91 22 3342 3000
 jyoti.parmar@crisil.com

Aditya Sarda
Director - CRISIL Ratings
CRISIL Limited
B:+91 124 672 2000
aditya.sarda@crisil.com


Rishabh Jain
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2192
rishabh.jain@crisil.com


Mehwash Qureshi
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2139
mehwash.qureshi@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL